Evidence-Based Project: Cost Savings and Reduction in Environmental Release With Low-Flow Anesthesia.


Journal

AANA journal
ISSN: 2162-5239
Titre abrégé: AANA J
Pays: United States
ID NLM: 0431420

Informations de publication

Date de publication:
Feb 2021
Historique:
entrez: 27 1 2021
pubmed: 28 1 2021
medline: 23 11 2021
Statut: ppublish

Résumé

Volatile anesthetic agents act as greenhouse gases. Low-flow anesthesia techniques (≤1 L/min) are associated with lower costs. Decreasing volatile anesthetic delivery provides safe and effective strategies for anesthesia providers to decrease costs and reduce environmental pollution. This evidence-based project aimed to estimate cost savings and reduction in the environmental release of anesthetic gases, under simulated lower fresh gas flow (FGF) practices. For each surgical case, the exhaled anesthetic gas percent and FGF data were used to calculate the volume of fluid volatile anesthetic. The fluid volatile anesthetic for each case was then estimated using simulated FGFs. Changes in volatile agent cost and environmental release of anesthetic gases were predicted. Sevoflurane was the most commonly used volatile agent. The mean FGF for cases using sevoflurane was 2.5 L/min. The simulated FGF of 1 L/min FGF across all agents predicted a 48% ($50,892) reduction in costs of volatile anesthetics and a 42% (33 metric tons of carbon dioxide equivalent) decrease in carbon emissions. Simulated low-flow anesthesia demonstrated cost savings and environmental conservation. Project findings align with current literature showing that lowering FGFs represents an area of cost containment and an opportunity to lessen the environmental impact of anesthesia.

Identifiants

pubmed: 33501906

Substances chimiques

Anesthetics, Inhalation 0
Carbon Dioxide 142M471B3J
Sevoflurane 38LVP0K73A

Types de publication

Journal Article

Langues

eng

Pagination

27-33

Informations de copyright

Copyright © by the American Association of Nurse Anesthetists.

Déclaration de conflit d'intérêts

The authors have declared no financial relationships with any commercial entity related to the content of this article. The authors did not discuss off-label use within the article. Disclosure statements are available for viewing upon request.

Auteurs

Alicia Edmonds (A)

contributed to this evidence-based project in fulfillment of the degree of Doctor of Nurse Anesthesia Practice at Gonzaga University and Providence Sacred Heart Medical Center in Spokane, Washington, in 2019. Email: edmondar@yahoo.com.

Hilary Stambaugh (H)

contributed to this evidence-based project in fulfillment of the degree of Doctor of Nurse Anesthesia Practice at Gonzaga University and Providence Sacred Heart Medical Center in 2019.

Scot Pettey (S)

is the DNAP program director at Gonzaga University and Providence Sacred Heart Medical Center.

Kenn B Daratha (KB)

is clinical research faculty for the Gonzaga University and Providence Sacred Heart Medical Center DNAP program.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH